{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:08:10Z","timestamp":1789844890934,"version":"4.0.1"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Fentanyl has spread through the illicit opioid supply in Canada, driving increasing overdose deaths. However, the effectiveness of methadone and buprenorphine-naloxone in treating opioid use disorder during the fentanyl era is unknown.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate methadone and buprenorphine-naloxone treatment duration, a core effectiveness outcome in the treatment of opioid use disorder, in Ontario, Canada, between 2014 and 2022.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This population-based, retrospective cohort study included individuals who initiated methadone or buprenorphine-naloxone between January 2014 and December 2022 in Ontario, Canada. Data were analyzed from July 18, 2023, to June 11, 2025.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Period of medication initiation (2014-2016, 2017-2019, or 2020-2022).<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The main outcome was treatment duration, measured as time to medication discontinuation (5 consecutive days without dispensation of the initial opioid agonist treatment or availability of take-home doses).<\/jats:p><\/jats:sec>Results<\/jats:title>The cohort included 72\u202f717 new recipients of opioid agonist treatments (45\u202f256 [62.2%] male; median [IQR] age, 35 [28-46] years), with 34\u202f538 individuals (47.5%) receiving methadone and 38\u202f179 individuals (52.5%) receiving buprenorphine-naloxone. Among individuals starting methadone, median treatment duration decreased from 193 (95% CI, 185-202) days in 2014 to 2016 to 139 (95% CI, 130-149) days in 2017 to 2019 and 86 (95% CI, 78-95) days in 2020 to 2022. Among individuals starting buprenorphine-naloxone, median treatment duration decreased from 51 (95% CI, 49-54) days in 2014 to 2016 and 50 (95% CI, 48-53) days in 2017 to 2019 to 38 (95% CI, 36-40) days in 2020 to 2022. In adjusted Cox regression models including time-varying effects and using 2014 to 2016 as the reference period, hazards of discontinuation measured at treatment initiation were higher during later periods of methadone initiation (2017-2019: adjusted hazard ratio [aHR], 1.18 [95% CI, 1.15-1.22]; P<\/jats:italic>\u2009&amp;lt;\u2009.001; 2020-2022: aHR, 1.45 [95% CI, 1.39-1.51]; P<\/jats:italic>\u2009&amp;lt;\u2009.001) and for buprenorphine-naloxone initiation in 2020 to 2022 (aHR, 1.11 [95% CI, 1.08-1.15]; P<\/jats:italic>\u2009&amp;lt;\u2009.001). Age categories, neighborhood income quintile, rurality, sex, and number of comorbidities were also associated with time to discontinuation in adjusted models.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This cohort study found that treatment duration among individuals starting methadone and buprenorphine-naloxone during 2020 to 2022 was lower than during 2014 to 2016. This study highlights the importance of ongoing evaluation of treatment effectiveness, given the dynamic nature of the opioid crisis. Further research is needed to improve treatment retention and improve the effectiveness of opioid use disorder treatment.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.18389","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:01:01Z","timestamp":1751382061000},"page":"e2518389","source":"Crossref","is-referenced-by-count":11,"title":["Duration of Methadone and Buprenorphine-Naloxone Treatment"],"prefix":"10.1001","volume":"8","author":[{"given":"Robert A.","family":"Kleinman","sequence":"first","affiliation":[{"name":"Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kurdyak","sequence":"additional","affiliation":[{"name":"Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Mental Health and Addictions Program, ICES, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"zoi250572r1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109464","article-title":"The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018: Findings from the OATS retrospective linkage study.","volume":"236","author":"Jones","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"zoi250572r3","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"9","key":"zoi250572r4","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1111\/add.15893","article-title":"Opioid withdrawal management in the fentanyl era.","volume":"117","author":"Thakrar","year":"2022","journal-title":"Addiction"},{"key":"zoi250572r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2024.100240","article-title":"Fentanyl, carfentanil and other fentanyl analogues in Canada\u2019s illicit opioid supply: A cross-sectional study.","author":"Kleinman","year":"2024","journal-title":"Drug Alcohol Depend Rep"},{"issue":"9","key":"zoi250572r7","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1111\/add.15875","article-title":"The opioid use disorder core outcomes set (OUD-COS) for treatment research: findings from a Delphi consensus study.","volume":"117","author":"Karnik","year":"2022","journal-title":"Addiction"},{"key":"zoi250572r8","doi-asserted-by":"publisher","first-page":"m772","DOI":"10.1136\/bmj.m772","article-title":"Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study.","volume":"368","author":"Pearce","year":"2020","journal-title":"BMJ"},{"key":"zoi250572r9","doi-asserted-by":"publisher","first-page":"k3532","DOI":"10.1136\/bmj.k3532","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE).","volume":"363","author":"Langan","year":"2018","journal-title":"BMJ"},{"key":"zoi250572r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109507","article-title":"Identifying key risk factors for premature discontinuation of opioid use disorder treatment in the United States: a predictive modeling study.","volume":"237","author":"Stafford","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"zoi250572r13","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1111\/add.15514","article-title":"The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15-year retrospective cohort study.","volume":"116","author":"Bharat","year":"2021","journal-title":"Addiction"},{"issue":"4","key":"zoi250572r14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/CXA.0000000000000192","article-title":"Opioid agonist treatment retention among people initiating methadone and buprenorphine across diverse demographic and geographic subgroups in Ontario: a population-based retrospective cohort study.","volume":"14","author":"Elnagdi","year":"2023","journal-title":"Can J Addict"},{"issue":"7","key":"zoi250572r15","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1111\/add.15862","article-title":"Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.","volume":"117","author":"Gomes","year":"2022","journal-title":"Addiction"},{"issue":"49","key":"zoi250572r16","doi-asserted-by":"publisher","first-page":"E1718","DOI":"10.1503\/cmaj.230968","article-title":"Using short-acting opioids to relieve opioid withdrawal in hospital.","volume":"195","author":"Kleinman","year":"2023","journal-title":"CMAJ"},{"issue":"32","key":"zoi250572r17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/adaw.33525","article-title":"Do patients addicted to fentanyl need higher doses of methadone or buprenorphine?","volume":"34","author":"Knopf","year":"2022","journal-title":"Alcohol Drug Abuse Week"},{"key":"zoi250572r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108832","article-title":"Adapting methadone inductions to the fentanyl era.","volume":"141","author":"Buresh","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"zoi250572r19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jsat.2017.01.004","article-title":"Characterizing fentanyl use in methadone-maintained clients.","volume":"75","author":"Arfken","year":"2017","journal-title":"J Subst Abuse Treat"},{"key":"zoi250572r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108031","article-title":"One year of methadone maintenance treatment in a fentanyl endemic area: safety, repeated exposure, retention, and remission.","volume":"115","author":"Stone","year":"2020","journal-title":"J Subst Abuse Treat"},{"issue":"8","key":"zoi250572r21","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1111\/add.16180","article-title":"Polydrug use among patients on methadone medication treatment: evidence from urine drug testing to inform patient safety.","volume":"118","author":"Saloner","year":"2023","journal-title":"Addiction"},{"issue":"23","key":"zoi250572r22","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1001\/jama.2023.21288","article-title":"Trends in before medically advised discharges for patients with opioid use disorder, 2016-2020.","volume":"330","author":"Thakrar","year":"2023","journal-title":"JAMA"},{"issue":"12","key":"zoi250572r23","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.7326\/M22-2964","article-title":"Retiring the \u201cagainst medical advice\u201d discharge.","volume":"175","author":"Kleinman","year":"2022","journal-title":"Ann Intern Med"},{"issue":"16","key":"zoi250572r24","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1001\/jama.2023.1207","article-title":"Trends in buprenorphine initiation and retention in the United States, 2016-2022.","volume":"329","author":"Chua","year":"2023","journal-title":"JAMA"},{"key":"zoi250572r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.209055","article-title":"Transitioning off methadone: a qualitative study exploring why patients discontinue methadone treatment for opioid use disorder.","volume":"150","author":"Thakrar","year":"2023","journal-title":"J Subst Use Addict Treat"},{"issue":"3","key":"zoi250572r26","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/ADM.0000000000001292","article-title":"Patients\u2019 perspectives on discontinuing buprenorphine for the treatment of opioid use disorder.","volume":"18","author":"Wyse","year":"2024","journal-title":"J Addict Med"},{"issue":"1","key":"zoi250572r27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1001\/jamapsychiatry.2021.3292","article-title":"Insights into mixing fentanyl and benzodiazepines from Canadian drug seizures.","volume":"79","author":"Pardo","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"zoi250572r28","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/ADM.0000000000000950","article-title":"Office-based methadone prescribing for opioid use disorder: the Canadian model.","volume":"16","author":"Kleinman","year":"2022","journal-title":"J Addict Med"},{"issue":"11","key":"zoi250572r29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.44528","article-title":"Rapid access addiction medicine clinics for people with problematic opioid use.","volume":"6","author":"Corace","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6","key":"zoi250572r30","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/ADM.0000000000001202","article-title":"ASAM clinical considerations: buprenorphine treatment of opioid use disorder for individuals using high-potency synthetic opioids.","volume":"17","author":"Weimer","year":"2023","journal-title":"J Addict Med"},{"issue":"4","key":"zoi250572r31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/ADM.0000000000001296","article-title":"High-dose buprenorphine initiation: a scoping review.","volume":"18","author":"Wong","year":"2024","journal-title":"J Addict Med"},{"issue":"2","key":"zoi250572r32","doi-asserted-by":"publisher","first-page":"283","DOI":"10.7326\/M21-3968","article-title":"Treating opioid withdrawal in the hospital: a role for short-acting opioids.","volume":"175","author":"Kleinman","year":"2022","journal-title":"Ann Intern Med"},{"issue":"6","key":"zoi250572r33","doi-asserted-by":"publisher","first-page":"e348","DOI":"10.1097\/ADM.0000000000001007","article-title":"Buprenorphine initiation in the era of high-potency synthetic opioids: a call for community-based participatory research to help learning health systems provide precision medicine for opioid use disorder.","volume":"16","author":"Fiellin","year":"2022","journal-title":"J Addict Med"},{"key":"zoi250572r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.111032","article-title":"Characteristics, treatment patterns and retention with extended-release subcutaneous buprenorphine for opioid use disorder: a population-based cohort study in Ontario, Canada.","volume":"254","author":"Iacono","year":"2024","journal-title":"Drug Alcohol Depend"},{"key":"zoi250572r35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076336","article-title":"Effect of risk mitigation guidance opioid and stimulant dispensations on mortality and acute care visits during dual public health emergencies: retrospective cohort study.","volume":"384","author":"Slaunwhite","year":"2024","journal-title":"BMJ"},{"key":"zoi250572r36","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071467","article-title":"Is daily supervised buprenorphine-naloxone dosing necessary?","volume":"378","author":"Kleinman","year":"2022","journal-title":"BMJ"},{"key":"zoi250572r2","volume-title":"ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update","author":"American Society of Addiction Medicine (ASAM)","year":"2020"},{"key":"zoi250572r10","volume-title":"Ontario Drug Programs Reference Manual","author":"Ministry of Health, Government of Ontario","year":"2023"},{"key":"zoi250572r37","volume-title":"Methadone Maintenance Treatment: Program Standards and Clinical Guidelines","author":"College of Physicians and Surgeons of Ontario","year":"2011"},{"key":"zoi250572r6","unstructured":"Bromley? L, Kahan? M, Regenstreif? L, Srivastava? A, Wyman? J. Methadone treatment for people who use fentanyl: recommendations. Accessed March 12, 2024. https:\/\/www.metaphi.ca\/wp-content\/uploads\/Guide_MethadoneForFentanyl.pdf"},{"key":"zoi250572r11","unstructured":"Public Health Ontario. Interactive Opioid Tool. Accessed June 7, 2025. https:\/\/www.publichealthontario.ca\/en\/Data-and-Analysis\/Substance-Use\/Interactive-Opioid-Tool#\/"},{"key":"zoi250572r38","unstructured":"Indigenous population continues to grow and is much younger than the non-Indigenous population, although the pace of growth has slowed. News release. Statistics Canada. September 21, 2022. Accessed July 10, 2024. https:\/\/www150.statcan.gc.ca\/n1\/daily-quotidien\/220921\/dq220921a-eng.htm"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2835845\/kleinman_2025_oi_250572_1750791787.5717.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:01:04Z","timestamp":1751382064000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2835845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.18389","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}